Insider Monkey73d agoneutral
New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth CatalystNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Simply Wall St.85d agoneutral
Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval Lands